Galimedix Therapeutics

Company Overview

Snapshot

Founded in June 2017 by Christopher Parsons, Herman Russ, and Andrew Pearlman, Galimedix Therapeutics operates with 1–10 employees. The company has raised $2 million across one funding round from InFocus Capital Partners and Rimonci Capital. In March 2024, Galimedix Therapeutics presented promising scientific data for its orally available small molecule GAL-201, indicating its potential for Alzheimer's disease treatment.

Business overview

Galimedix Therapeutics is a Phase 2 clinical-stage biotechnology company focused on developing novel oral and topical neuroprotective therapies for serious eye and brain diseases. The company's core technology involves groundbreaking small molecules that target amyloid beta, aiming to revolutionize treatments for conditions such as dry Age-related Macular Degeneration (AMD), glaucoma, and Alzheimer's disease. Galimedix operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology, with a focus on Drugs Discovery & Development, serving the healthcare and life sciences industries.

Strategic signal

In March 2024, Galimedix Therapeutics presented encouraging data for its orally available small molecule GAL-201 at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024). This data highlights GAL-201's potential as a neuroprotective therapy for Alzheimer's disease by acting upstream of other known amyloid beta-targeting agents. This development signals a significant step forward in the company's clinical pipeline and validates its amyloid beta-targeting approach, suggesting strong growth potential in the neurodegenerative disease market.

Company Intelligence Q&A

What was the key announcement made by Galimedix Therapeutics in March 2024?

In March 2024, Galimedix Therapeutics presented scientific data at AD/PD™ 2024, demonstrating promising neuroprotective effects of its orally available small molecule, GAL-201, for the treatment of Alzheimer’s disease.

What preclinical data did Galimedix Therapeutics announce in February 2024?

In February 2024, Galimedix Therapeutics announced new preclinical data for GAL-201 in an Alzheimer's disease transgenic model, which was subsequently presented at the AD/PD™ 2024 Conference. The data showed beneficial effects in suppressing toxic amyloid beta aggregates.

What was the significance of Biogen's Aducanumab Phase 3 results for Galimedix Therapeutics in October 2019?

In October 2019, Galimedix Therapeutics announced that the positive Phase 3 results of.

What did preclinical studies demonstrate about GAL-101 in May 2019?

In May 2019, preclinical studies demonstrated that Galimedix Therapeutics' investigational compound GAL-101 showed neuroprotective effects from toxic amyloid beta in dry AMD and glaucoma models, with data presented at the ARVO Annual Meeting.

What information did Galimedix Therapeutics present at the Glaucoma 360 Conference in February 2019?

In February 2019, Galimedix Therapeutics presented data at the Glaucoma 360 Conference, showcasing the safety, tolerability, and potential efficacy of its investigational eyedrops containing GAL-101 for ophthalmic diseases.